ANLN is overexpressed in different tumor types, including breast cancer (Downs et al., 2019), lung cancer (Suzuki et al., 2005; Deng et al., 2021), pancreatic cancer (Idichi et al., 2017; Wang et al., 2019), liver cancer (Lian et al., 2018), bladder cancer (Zeng et al., 2017), and colorectal cancer (Wang et al., 2016). Here, ANLN is linked to urinary bladder cancer.